Funded Startups in Broomfield
Across these 12 Broomfield-area entries, the largest disclosed round is Biodesix’s $55M on 2024-04-05; it sits above the other disclosed amounts, with the…
Across these 12 Broomfield-area entries, the largest disclosed round is Biodesix’s $55M on 2024-04-05; it sits above the other disclosed amounts, with the next-highest disclosed figure being FusionAuth’s $65M (2023-11-01) and several others clustered in the $10M–$35M range. Disclosed amounts vary widely, but the low end is visible in multiple entries marked undisclosed, including Tru Consulting (2024-09-03) and WaveLynx Technologies (2023-10-16).
The dataset shows a tight temporal run: 2024 accounts for 7 of the 12 rows, including a dense cluster from 2024-01-23 (Albedo, $35M) through 2024-04-05 (Biodesix, $55M). Stage labels are also mixed—only a subset are explicitly tagged (e.g., Albedo as Series A on 2024-01-23; Alio as Series C on 2022-12-08), while 5 of 12 entries use “Series Unknown” and 2 of 12 are “undisclosed.” Sector-wise, biotechnology appears repeatedly (Biodesix and Biofire twice), alongside recurring data/analytics entries such as Albedo ($35M, 2024-01-23) and ikeGPS ($13M, 2025-07-10). The rows span 2020-12-10 (Xero Shoes, $13M) to the most recent 2026-05-14 (Liqid, $8M).
Most recent rounds
12 shownRelated listings
Frequently asked
Which disclosed round is the outlier, and how does it compare to the next-largest disclosed amount in Broomfield?
Among disclosed amounts, FusionAuth’s $65M (2023-11-01) is the top figure, and it sits above Biodesix’s next-largest disclosed $55M (2024-04-05). Most other disclosed rounds fall below those levels, including Albedo’s $35M (2024-01-23) and Alio’s $18M (2022-12-08).
Does the activity cluster in time within this list, or are the rounds evenly spread?
They cluster heavily in 2024: 7 of 12 rows have 2024 round dates, spanning 2024-01-23 (Albedo, $35M) through 2024-09-03 (Tru Consulting, undisclosed). By contrast, only 1 row each appears in 2025 and 2026 (ikeGPS on 2025-07-10 for $13M; Liqid on 2026-05-14 for $8M).
How often are stage labels missing, and does that affect interpretation of the “dominant” stage?
Stage information is incomplete for a majority of entries: 5 of 12 are “Series Unknown” (e.g., Liqid 2026-05-14, ikeGPS 2025-07-10), and 2 of 12 are “undisclosed” on the amount field (Tru Consulting 2024-09-03; Biofire 2024-01-01). Only a minority have explicit tags, such as Albedo as Series A ($35M on 2024-01-23) and Alio as Series C ($18M on 2022-12-08).
Are any sectors over-represented in these 12 Broomfield rows?
Biotechnology is the clearest repeat sector, appearing in 3 rows: Biodesix ($55M on 2024-04-05) and Biofire twice (2024-01-01 undisclosed; 2022-11-07 $14M). Data and Analytics also recurs with Albedo ($35M on 2024-01-23) and ikeGPS ($13M on 2025-07-10).
Which entries fall in the most recent 90-day window represented here?
Using the latest date in the table (2026-05-14), only Liqid (2026-05-14, $8M) and the prior entry, ikeGPS (2025-07-10, $13M), are within the covered range, but only Liqid is within 90 days of 2026-05-14. The next most recent date after 2025-07-10 is 2024-09-03 (Tru Consulting, undisclosed), which is outside that 90-day window.
Are there smaller disclosed amounts that consistently sit near the bottom of this list?
The lowest disclosed amount shown is Liqid’s $8M (2026-05-14). Several other disclosed figures are relatively low versus the top rounds—10M appears for PASCAL on 2024-03-25 ($10M) and 13M appears for ikeGPS (2025-07-10, $13M) and Xero Shoes (2020-12-10, $13M)—but none undercut the $8M floor.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.